{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:34Z","timestamp":1792027354647,"version":"4.4.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40265-016-0610-3","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T08:49:38Z","timestamp":1468399778000},"page":"1161-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients"],"prefix":"10.1007","volume":"76","author":[{"given":"Antonio","family":"D\u2019Avolio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Pensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Baietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"610_CR1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-13-66","volume":"13","author":"CC Lai","year":"2013","unstructured":"Lai CC, Sheng WH, Wang JT, Cheng A, Chuang YC, Chen YC, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013;13:66.","journal-title":"BMC Infect Dis."},{"issue":"21","key":"610_CR2","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323\u20139.","journal-title":"JAMA."},{"issue":"7","key":"610_CR3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med."},{"issue":"4","key":"610_CR4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00003495-200464040-00009","volume":"64","author":"C Fenton","year":"2004","unstructured":"Fenton C, Keating GM, Curran MP. Daptomycin. Drugs. 2004;64(4):445\u201355 (discussion 57\u20138).","journal-title":"Drugs."},{"issue":"15","key":"610_CR5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2165\/00003495-200464150-00002","volume":"64","author":"M Raghavan","year":"2004","unstructured":"Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs. 2004;64(15):1621\u201342.","journal-title":"Drugs."},{"issue":"7","key":"610_CR6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1592\/phco.29.7.792","volume":"29","author":"JC Gallagher","year":"2009","unstructured":"Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009;29(7):792\u20139.","journal-title":"Pharmacotherapy."},{"key":"610_CR7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2334-14-92","volume":"14","author":"C Vazquez-Guillamet","year":"2014","unstructured":"Vazquez-Guillamet C, Kollef MH. Treatment of gram-positive infections in critically ill patients. BMC Infect Dis. 2014;14:92.","journal-title":"BMC Infect Dis."},{"issue":"5","key":"610_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijantimicag.2014.08.002","volume":"44","author":"JM Munita","year":"2014","unstructured":"Munita JM, Murray BE, Arias CA. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents. 2014;44(5):387\u201395.","journal-title":"Int J Antimicrob Agents."},{"issue":"3","key":"610_CR9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","volume":"45","author":"A Louie","year":"2001","unstructured":"Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2001;45(3):845\u201351.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"610_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","volume":"48","author":"N Safdar","year":"2004","unstructured":"Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"610_CR11","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","volume":"44","author":"FB Oleson Jr","year":"2000","unstructured":"Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44(11):2948\u201353.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"610_CR12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","volume":"8","author":"FP Tally","year":"1999","unstructured":"Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 1999;8(8):1223\u201338.","journal-title":"Expert Opin Investig Drugs."},{"issue":"12","key":"610_CR13","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","volume":"50","author":"SM Bhavnani","year":"2010","unstructured":"Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568\u201374.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"610_CR14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/524086","volume":"46","author":"S Bonora","year":"2008","unstructured":"Bonora S, Lanzafame M, D\u2019Avolio A, Trentini L, Lattuada E, Concia E, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis. 2008;46(1):146\u20137.","journal-title":"Clin Infect Dis."},{"issue":"15","key":"610_CR15","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/01.aids.0000247121.19951.fa","volume":"20","author":"D Gonzalez de Requena","year":"2006","unstructured":"Gonzalez de Requena D, Calcagno A, Bonora S, Ladetto L, D\u2019Avolio A, Sciandra M, et al. Unexpected drug\u2013drug interaction between tipranavir\/ritonavir and enfuvirtide. AIDS. 2006;20(15):1977\u20139.","journal-title":"AIDS."},{"key":"610_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2014.05.007","volume":"77","author":"M Hites","year":"2014","unstructured":"Hites M, Dell\u2019Anna AM, Scolletta S, Taccone FS. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev. 2014;77:12\u201321.","journal-title":"Adv Drug Deliv Rev."},{"issue":"4","key":"610_CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10156-003-0279-X","volume":"9","author":"DP Nicolau","year":"2003","unstructured":"Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother. 2003;9(4):292\u20136.","journal-title":"J Infect Chemother."},{"issue":"3","key":"610_CR18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840\u201351 (quiz 59).","journal-title":"Crit Care Med."},{"issue":"10","key":"610_CR19","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"610_CR20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"BH Dvorchik","year":"2003","unstructured":"Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318\u201323.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 1","key":"610_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1469-0691.2006.01342.x","volume":"12","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2006;12(Suppl 1):24\u201332.","journal-title":"Clin Microbiol Infect."},{"issue":"2","key":"610_CR22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","volume":"36","author":"JR Woodworth","year":"1992","unstructured":"Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36(2):318\u201325.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"610_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.46.1.31-33.2002","volume":"46","author":"R Wise","year":"2002","unstructured":"Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46(1):31\u20133.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"610_CR24","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","volume":"48","author":"B Dvorchik","year":"2004","unstructured":"Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48(8):2799\u2013807.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"610_CR25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","volume":"37","author":"C Reiber","year":"2015","unstructured":"Reiber C, Senn O, Muller D, Kullak-Ublick GA, Corti N. Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis. Ther Drug Monit. 2015;37(5):634\u201340.","journal-title":"Ther Drug Monit."},{"issue":"3","key":"610_CR26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","volume":"42","author":"A Paolo Di","year":"2013","unstructured":"Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):250\u20135.","journal-title":"Int J Antimicrob Agents."},{"issue":"4","key":"610_CR27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","volume":"19","author":"M Falcone","year":"2013","unstructured":"Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d\u2019Ettorre G, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19(4):732\u20139.","journal-title":"J Infect Chemother."},{"issue":"7\u20138","key":"610_CR28","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1345\/aph.1P745","volume":"45","author":"F Pea","year":"2011","unstructured":"Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011;45(7\u20138):e37.","journal-title":"Ann Pharmacother."},{"issue":"1","key":"610_CR29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s15010-013-0511-2","volume":"42","author":"F Pea","year":"2013","unstructured":"Pea F, Crapis M, Cojutti P, Bassetti M. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection. 2013;42(1):207\u201310.","journal-title":"Infection."},{"issue":"6","key":"610_CR30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/1389200215666140605130935","volume":"15","author":"L Baietto","year":"2014","unstructured":"Baietto L, Corcione S, Pacini G, Di Perri G, D\u2019Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab. 2014;15(6):581\u201398.","journal-title":"Curr Drug Metab."},{"issue":"12","key":"610_CR31","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/AAC.00781-10","volume":"54","author":"A Schipani","year":"2010","unstructured":"Schipani A, Siccardi M, D\u2019Avolio A, Baietto L, Simiele M, Bonora S, et al. Population pharmacokinetic modeling of the association between 63396C\u2192T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010;54(12):5242\u201350.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"610_CR32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jhep.2013.04.038","volume":"59","author":"A D\u2019Avolio","year":"2013","unstructured":"D\u2019Avolio A, Cusato J, Calcagno A, Di Perri G. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring? J Hepatol. 2013;59(3):633\u20134.","journal-title":"J Hepatol."},{"issue":"8","key":"610_CR33","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1128\/AAC.00090-07","volume":"51","author":"S Lemaire","year":"2007","unstructured":"Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother. 2007;51(8):2748\u201357.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"610_CR34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jac\/dku368","volume":"70","author":"L Baietto","year":"2015","unstructured":"Baietto L, D\u2019Avolio A, Cusato J, Pace S, Calcagno A, Motta I, et al. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2015;70(1):307\u20138.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"610_CR35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00216-009-3263-1","volume":"396","author":"L Baietto","year":"2010","unstructured":"Baietto L, D\u2019Avolio A, De Rosa FG, Garazzino S, Michelazzo M, Ventimiglia G, et al. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal Bioanal Chem. 2010;396(2):791\u20138.","journal-title":"Anal Bioanal Chem."},{"key":"610_CR36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpba.2013.08.022","volume":"88","author":"L Baietto","year":"2014","unstructured":"Baietto L, D\u2019Avolio A, Pace S, Simiele M, Marra C, Ariaudo A, et al. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J Pharm Biomed Anal. 2014;88:66\u201370.","journal-title":"J Pharm Biomed Anal."},{"issue":"2","key":"610_CR37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0b013e3181d3f5cb","volume":"32","author":"M Polillo","year":"2010","unstructured":"Polillo M, Tascini C, Lastella M, Malacarne P, Ciofi L, Viaggi B, et al. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit. 2010;32(2):200\u20135.","journal-title":"Ther Drug Monit."},{"issue":"6","key":"610_CR38","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.02355-14","volume":"58","author":"MP Pai","year":"2014","unstructured":"Pai MP, Russo A, Novelli A, Venditti M, Falcone M. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother. 2014;58(6):3162\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"610_CR39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2014.03.040","volume":"101","author":"A D\u2019Avolio","year":"2014","unstructured":"D\u2019Avolio A, Pensi D, Baietto L, Di Perri G. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. 2014;101:183\u201393.","journal-title":"J Pharm Biomed Anal."},{"issue":"3","key":"610_CR40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/eri.13.3","volume":"11","author":"I Kanzler","year":"2013","unstructured":"Kanzler I, Weis F, Beiras-Fernandez A. Current use of daptomycin in cardiac surgery and postoperative intensive care. Expert Rev Anti Infect Ther. 2013;11(3):309\u201320.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"9","key":"610_CR41","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2009.09.012","volume":"31","author":"G Sakoulas","year":"2009","unstructured":"Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31(9):1936\u201345.","journal-title":"Clin Ther."},{"key":"610_CR42","volume-title":"Cubicin (daptomycin). EMEA\/H\/C\/000637","author":"European Medicines Agency","year":"2006","unstructured":"European Medicines Agency. Cubicin (daptomycin). EMEA\/H\/C\/000637. London: European Medicines Agency; 2006."},{"issue":"3","key":"610_CR43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1389557511209030202","volume":"12","author":"C Vilhena","year":"2012","unstructured":"Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem. 2012;12(3):202\u20139.","journal-title":"Mini Rev Med Chem."},{"issue":"36","key":"610_CR44","doi-asserted-by":"crossref","first-page":"27501","DOI":"10.1074\/jbc.R110.128181","volume":"285","author":"L Robbel","year":"2010","unstructured":"Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem. 2010;285(36):27501\u20138.","journal-title":"J Biol Chem."},{"issue":"8","key":"610_CR45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.7164\/antibiotics.41.1093","volume":"41","author":"M Debono","year":"1988","unstructured":"Debono M, Abbott BJ, Molloy RM, Fukuda DS, Hunt AH, Daupert VM, et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot (Tokyo). 1988;41(8):1093\u2013105.","journal-title":"J Antibiot (Tokyo)."},{"issue":"1","key":"610_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0006-291X(80)91225-5","volume":"96","author":"M Yazawa","year":"1980","unstructured":"Yazawa M, Yagi K. The amino acid sequence of the calmodulin obtained from sea anemone (metridium senile) muscle. Biochem Biophys Res Commun. 1980;96(1):377\u201381.","journal-title":"Biochem Biophys Res Commun."},{"key":"610_CR47","unstructured":"US FDA. Daptomycin (marketed as Cubicin) information. 2014. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm220282.htm . Accessed 6 June 2016."},{"issue":"3","key":"610_CR48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/2047-783X-16-3-115","volume":"16","author":"C Eckmann","year":"2011","unstructured":"Eckmann C, Dryden M, Montravers P, Kozlov R, Sganga G. Antimicrobial treatment of \u201ccomplicated\u201d intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res. 2011;16(3):115\u201326.","journal-title":"Eur J Med Res."},{"key":"610_CR49","unstructured":"European Medicines Agency. Cubicin: EPAR\u2014scientific discussion (WC500036046.pdf). European Medicines Agency; 2006."},{"key":"610_CR50","unstructured":"European Medicines Agency. Cubicin: EPAR\u2014product information (WC500036049.pdf). European Medicines Agency; 2006."},{"issue":"8","key":"610_CR51","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","volume":"47","author":"JA Silverman","year":"2003","unstructured":"Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(8):2538\u201344.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"610_CR52","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1039\/b416648p","volume":"22","author":"RH Baltz","year":"2005","unstructured":"Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep. 2005;22(6):717\u201341.","journal-title":"Nat Prod Rep."},{"issue":"4","key":"610_CR53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00249-007-0227-2","volume":"37","author":"SW Ho","year":"2008","unstructured":"Ho SW, Jung D, Calhoun JR, Lear JD, Okon M, Scott WR, et al. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur Biophys J. 2008;37(4):421\u201333.","journal-title":"Eur Biophys J."},{"issue":"7","key":"610_CR54","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.chembiol.2004.04.020","volume":"11","author":"D Jung","year":"2004","unstructured":"Jung D, Rozek A, Okon M, Hancock RE. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004;11(7):949\u201357.","journal-title":"Chem Biol."},{"issue":"4","key":"610_CR55","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bbamem.2011.01.001","volume":"1808","author":"JK Muraih","year":"2011","unstructured":"Muraih JK, Pearson A, Silverman J, Palmer M. Oligomerization of daptomycin on membranes. Biochim Biophys Acta. 2011;1808(4):1154\u201360.","journal-title":"Biochim Biophys Acta."},{"issue":"9","key":"610_CR56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbamem.2006.02.009","volume":"1758","author":"SK Straus","year":"2006","unstructured":"Straus SK, Hancock RE. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta. 2006;1758(9):1215\u201323.","journal-title":"Biochim Biophys Acta."},{"key":"610_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","volume":"1277","author":"AS Bayer","year":"2013","unstructured":"Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139\u201358.","journal-title":"Ann N Y Acad Sci."},{"issue":"2","key":"610_CR58","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkt396","volume":"69","author":"O Gasch","year":"2014","unstructured":"Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother. 2014;69(2):568\u201371.","journal-title":"J Antimicrob Chemother."},{"issue":"10","key":"610_CR59","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1473-3099(09)70200-2","volume":"9","author":"PA Moise","year":"2009","unstructured":"Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9(10):617\u201324.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"610_CR60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10096-007-0455-5","volume":"27","author":"M Sharma","year":"2008","unstructured":"Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27(6):433\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"11","key":"610_CR61","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/AAC.01184-13","volume":"57","author":"SJ Yang","year":"2013","unstructured":"Yang SJ, Mishra NN, Rubio A, Bayer AS. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother. 2013;57(11):5658\u201364.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"610_CR62","doi-asserted-by":"crossref","first-page":"e58469","DOI":"10.1371\/journal.pone.0058469","volume":"8","author":"Y Song","year":"2013","unstructured":"Song Y, Rubio A, Jayaswal RK, Silverman JA, Wilkinson BJ. Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies. PLoS One. 2013;8(3):e58469.","journal-title":"PLoS One."},{"issue":"9","key":"610_CR63","doi-asserted-by":"crossref","first-page":"e107426","DOI":"10.1371\/journal.pone.0107426","volume":"9","author":"NN Mishra","year":"2014","unstructured":"Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One. 2014;9(9):e107426.","journal-title":"PLoS One."},{"issue":"9","key":"610_CR64","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00223-11","volume":"55","author":"NN Mishra","year":"2011","unstructured":"Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(9):4012\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"610_CR65","doi-asserted-by":"crossref","first-page":"e71151","DOI":"10.1371\/journal.pone.0071151","volume":"8","author":"NN Mishra","year":"2013","unstructured":"Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, et al. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One. 2013;8(8):e71151.","journal-title":"PLoS One."},{"issue":"6","key":"610_CR66","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/AAC.01682-08","volume":"53","author":"NN Mishra","year":"2009","unstructured":"Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(6):2312\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"610_CR67","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","volume":"15","author":"J Goncalves-Pereira","year":"2011","unstructured":"Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care. 2011;15(5):R206.","journal-title":"Crit Care."},{"issue":"4","key":"610_CR68","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.41.4.733","volume":"41","author":"JW Mouton","year":"1997","unstructured":"Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997;41(4):733\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"610_CR69","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2007.02.012","volume":"30","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents. 2007;30(3):202\u20139.","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"610_CR70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkm137","volume":"60","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and\/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60(1):7\u201319.","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"610_CR71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","volume":"54","author":"CL Moore","year":"2012","unstructured":"Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51\u20138.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"610_CR72","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","volume":"43","author":"PA Moise","year":"2009","unstructured":"Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg\/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7):1211\u20139.","journal-title":"Ann Pharmacother."},{"issue":"2","key":"610_CR73","first-page":"109","volume":"28","author":"F Ballester","year":"2015","unstructured":"Ballester F, Pujol I, Cueto P, Rovira C, Iftimie S, Camps J. Emergence of daptomycin-resistant Enterococcus faecium in a critically ill patient with postoperative intra-abdominal sepsis. Rev Esp Quimioter. 2015;28(2):109\u201310.","journal-title":"Rev Esp Quimioter."},{"issue":"4","key":"610_CR74","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","volume":"49","author":"JS Lewis 2nd","year":"2005","unstructured":"Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49(4):1664\u20135.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"610_CR75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","volume":"45","author":"HW Boucher","year":"2007","unstructured":"Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601\u20138.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"610_CR76","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1128\/AAC.00347-11","volume":"55","author":"M Steed","year":"2011","unstructured":"Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(7):3522\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"610_CR77","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1128\/AAC.00084-11","volume":"55","author":"ME Steed","year":"2011","unstructured":"Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz GW, Rybak MJ. Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(10):4748\u201354.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"610_CR78","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/AAC.05849-11","volume":"56","author":"ME Steed","year":"2012","unstructured":"Steed ME, Vidaillac C, Rybak MJ. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56(2):955\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"610_CR79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","volume":"39","author":"AM Vilay","year":"2011","unstructured":"Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39(1):19\u201325.","journal-title":"Crit Care Med."},{"issue":"7","key":"610_CR80","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.01741-10","volume":"55","author":"R Kullar","year":"2011","unstructured":"Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55(7):3505\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 3","key":"610_CR81","first-page":"iii35","volume":"62","author":"DP Levine","year":"2008","unstructured":"Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother. 2008;62(Suppl 3):iii35\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"610_CR82","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e31820f6575","volume":"30","author":"SM Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg\/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2011;30(8):712\u20134.","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"610_CR83","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/ndt\/gfp704","volume":"25","author":"JT Kielstein","year":"2010","unstructured":"Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis: a pharmacokinetic study. Nephrol Dial Transplant. 2010;25(5):1537\u201341.","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"610_CR84","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","volume":"294","author":"S Uchino","year":"2005","unstructured":"Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813\u20138.","journal-title":"JAMA."},{"issue":"1","key":"610_CR85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkm405","volume":"61","author":"O Burkhardt","year":"2008","unstructured":"Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother. 2008;61(1):224\u20135.","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"610_CR86","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/ndt\/gfp035","volume":"24","author":"R Faulhaber-Walter","year":"2009","unstructured":"Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, et al. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant. 2009;24(7):2179\u201386.","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"610_CR87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ncpneph0060","volume":"2","author":"D Fliser","year":"2006","unstructured":"Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol. 2006;2(1):32\u20139.","journal-title":"Nat Clin Pract Nephrol."},{"issue":"2","key":"610_CR88","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/ajkd.2000.8973","volume":"36","author":"VA Kumar","year":"2000","unstructured":"Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000;36(2):294\u2013300.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"610_CR89","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1523-1755.2001.060002777.x","volume":"60","author":"MR Marshall","year":"2001","unstructured":"Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 2001;60(2):777\u201385.","journal-title":"Kidney Int."},{"issue":"9","key":"610_CR90","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1525-1594.2003.07283.x","volume":"27","author":"BA Mueller","year":"2003","unstructured":"Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs. 2003;27(9):808\u201314.","journal-title":"Artif Organs."},{"issue":"2","key":"610_CR91","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s15010-012-0300-3","volume":"41","author":"B Preiswerk","year":"2012","unstructured":"Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection. 2012;41(2):553\u20137.","journal-title":"Infection."},{"issue":"2","key":"610_CR92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000353400","volume":"59","author":"N Corti","year":"2013","unstructured":"Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy. 2013;59(2):143\u201351.","journal-title":"Chemotherapy."},{"issue":"4","key":"610_CR93","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkr551","volume":"67","author":"JM Wenisch","year":"2012","unstructured":"Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012;67(4):977\u201383.","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"610_CR94","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2013.02.009","volume":"42","author":"RL Soon","year":"2013","unstructured":"Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J. Pharmacokinetic\/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents. 2013;42(1):53\u20138.","journal-title":"Int J Antimicrob Agents."},{"issue":"2","key":"610_CR95","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","volume":"49","author":"DA Figueroa","year":"2009","unstructured":"Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177\u201380.","journal-title":"Clin Infect Dis."},{"issue":"9","key":"610_CR96","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","volume":"62","author":"DE Katz","year":"2008","unstructured":"Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62(9):1455\u201364.","journal-title":"Int J Clin Pract."},{"issue":"12","key":"610_CR97","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","volume":"68","author":"R Kullar","year":"2013","unstructured":"Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921\u20136.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"610_CR98","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","volume":"31","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31(6):527\u201336.","journal-title":"Pharmacotherapy."},{"issue":"3","key":"610_CR99","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","volume":"71","author":"R Kullar","year":"2016","unstructured":"Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother. 2016;71(3):576\u201386.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"610_CR100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","volume":"36","author":"M Bassetti","year":"2010","unstructured":"Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36(5):459\u201361.","journal-title":"Int J Antimicrob Agents."},{"issue":"11","key":"610_CR101","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","volume":"57","author":"M Falcone","year":"2013","unstructured":"Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568\u201376.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"610_CR102","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/cid\/ciu230","volume":"58","author":"A Paolo Di","year":"2014","unstructured":"Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis. 2014;58(12):1788\u20139.","journal-title":"Clin Infect Dis."},{"issue":"5","key":"610_CR103","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601\u20137.","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"610_CR104","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijantimicag.2011.03.006","volume":"38","author":"G Wu","year":"2011","unstructured":"Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents. 2011;38(3):192\u20136.","journal-title":"Int J Antimicrob Agents."},{"issue":"6","key":"610_CR105","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1128\/AAC.01404-10","volume":"55","author":"MH Nguyen","year":"2011","unstructured":"Nguyen MH, Eells SJ, Tan J, Sheth CT, Omari B, Flores M, et al. Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery. Antimicrob Agents Chemother. 2011;55(6):2499\u2013505.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"610_CR106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/1440-1681.12195","volume":"41","author":"AH Salem","year":"2014","unstructured":"Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437\u201343.","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"2","key":"610_CR107","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","volume":"57","author":"JM Butterfield","year":"2013","unstructured":"Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, et al. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013;57(2):864\u201372.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"610_CR108","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2215\/CJN.08510910","volume":"6","author":"KE Cardone","year":"2011","unstructured":"Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, et al. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol. 2011;6(5):1081\u20138.","journal-title":"Clin J Am Soc Nephrol."},{"key":"610_CR109","doi-asserted-by":"crossref","unstructured":"Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791\u2013815, vii.","DOI":"10.1016\/j.idc.2009.06.008"},{"issue":"2","key":"610_CR110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","volume":"53","author":"JS Bubalo","year":"2009","unstructured":"Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(2):428\u201334.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"610_CR111","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1179\/1973947812Y.0000000033","volume":"24","author":"M Falcone","year":"2012","unstructured":"Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, Fallani S, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother. 2012;24(5):253\u20136.","journal-title":"J Chemother."},{"issue":"5","key":"610_CR112","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/mus.880060507","volume":"6","author":"DJ Newham","year":"1983","unstructured":"Newham DJ, Jones DA, Edwards RH. Large delayed plasma creatine kinase changes after stepping exercise. Muscle Nerve. 1983;6(5):380\u20135.","journal-title":"Muscle Nerve."},{"issue":"1","key":"610_CR113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00429029","volume":"52","author":"TD Noakes","year":"1983","unstructured":"Noakes TD, Kotzenberg G, McArthur PS, Dykman J. Elevated serum creatine kinase MB and creatine kinase BB-isoenzyme fractions after ultra-marathon running. Eur J Appl Physiol Occup Physiol. 1983;52(1):75\u20139.","journal-title":"Eur J Appl Physiol Occup Physiol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0610-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0610-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T01:19:51Z","timestamp":1656811191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0610-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":113,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0610-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}